|Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.|
|Jump to Full Text|
|PMID: 23202794 Owner: NLM Status: MEDLINE|
|GNRH significantly inhibits proliferation of a proportion of cancer cell lines by activating GNRH receptor (GNRHR)-G protein signaling. Therefore, manipulation of GNRHR signaling may have an under-utilized role in treating certain breast and ovarian cancers. However, the precise signaling pathways necessary for the effect and the features of cellular responses remain poorly defined. We used transcriptomic and proteomic profiling approaches to characterize the effects of GNRHR activation in sensitive cells (HEK293-GNRHR, SCL60) in vitro and in vivo, compared to unresponsive HEK293. Analyses of gene expression demonstrated a dynamic response to the GNRH superagonist Triptorelin. Early and mid-phase changes (0.5-1.0 h) comprised mainly transcription factors. Later changes (8-24 h) included a GNRH target gene, CGA, and up- or downregulation of transcripts encoding signaling and cell division machinery. Pathway analysis identified altered MAPK and cell cycle pathways, consistent with occurrence of G(2)/M arrest and apoptosis. Nuclear factor kappa B (NF-κB) pathway gene transcripts were differentially expressed between control and Triptorelin-treated SCL60 cultures. Reverse-phase protein and phospho-proteomic array analyses profiled responses in cultured cells and SCL60 xenografts in vivo during Triptorelin anti-proliferation. Increased phosphorylated NF-κB (p65) occurred in SCL60 in vitro, and p-NF-κB and IκBε were higher in treated xenografts than controls after 4 days Triptorelin. NF-κB inhibition enhanced the anti-proliferative effect of Triptorelin in SCL60 cultures. This study reveals details of pathways interacting with intense GNRHR signaling, identifies potential anti-proliferative target genes, and implicates the NF-κB survival pathway as a node for enhancing GNRH agonist-induced anti-proliferation.|
|Colette Meyer; Andrew H Sims; Kevin Morgan; Beth Harrison; Morwenna Muir; Jianing Bai; Dana Faratian; Robert P Millar; Simon P Langdon|
Related Documents :
|19549074 - Fibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocyte diffe...
7287824 - Evaluation of mg2+ as an intracellular regulator of uridine uptake.
24113574 - Substrate stiffness regulates temporary nf-κb activation via actomyosin contractions.
15571254 - Selective increase of datp pools upon activation of deoxycytidine kinase in lymphocytes...
24556414 - Nitrite augments glucose uptake in adipocytes through the protein kinase a-dependent st...
7504474 - Angiotensin ii mediates intracellular signalling in vascular smooth muscle cells by act...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2013-02-18|
|Title: Endocrine-related cancer Volume: 20 ISSN: 1479-6821 ISO Abbreviation: Endocr. Relat. Cancer Publication Date: 2013 Feb|
|Created Date: 2013-02-19 Completed Date: 2013-07-02 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 9436481 Medline TA: Endocr Relat Cancer Country: England|
|Languages: eng Pagination: 123-36 Citation Subset: IM|
|Breakthrough Breast Cancer Research Unit and Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Agents, Hormonal / pharmacology
Biological Markers / metabolism*
Enzyme Inhibitors / pharmacology
Gene Expression Profiling*
Kidney / cytology, metabolism
NF-kappa B / antagonists & inhibitors, genetics, metabolism*
Oligonucleotide Array Sequence Analysis
Phosphoproteins / immunology, metabolism
Protein Array Analysis*
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Receptors, LHRH / genetics, metabolism*
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction / drug effects
Triptorelin Pamoate / analogs & derivatives, pharmacology
|//Medical Research Council|
|0/Antineoplastic Agents, Hormonal; 0/Biological Markers; 0/Enzyme Inhibitors; 0/NF-kappa B; 0/Phosphoproteins; 0/RNA, Messenger; 0/Receptors, LHRH; 57773-63-4/Triptorelin Pamoate; TKG3I66TVE/deslorelin|
Journal ID (nlm-ta): Endocr Relat Cancer
Journal ID (iso-abbrev): Endocr. Relat. Cancer
Journal ID (publisher-id): ERC
Publisher: Society for Endocrinology, Bristol
© 2013 Society for Endocrinology
Revision Received Day: 22 Month: 11 Year: 2012
Accepted Day: 29 Month: 11 Year: 2012
Print publication date: Month: 2 Year: 2013
epreprint publication date: Day: 30 Month: 11 Year: 2012
Volume: 20 Issue: 1
First Page: 123 Last Page: 136
PubMed Id: 23202794
Publisher Id: ERC120192
|Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation Alternate Title:Anti-proliferative GNRH signaling|
|Andrew H Sims|
|Robert P Millar23|
|Simon P Langdon|
|Breakthrough Breast Cancer Research Unit and Division of PathologyInstitute of Genetics and Molecular Medicine, University of EdinburghCrewe Road South, Edinburgh, EH4 2XUUK
1Medical Research Council Human Reproductive Sciences UnitQueen's Medical Research Institute47 Little France Crescent, Edinburgh, EH16 4TJUK
2Centre for Integrative PhysiologyUniversity of EdinburghEdinburgh, EH8 9XDUK
3Mammal Research InstituteUniversity Pretoria and UCT/MRC Receptor Biology Unit, University of Cape TownCape TownSouth Africa
|Correspondence: Correspondence should be addressed to S P Langdon Email email@example.com)
GNRH analog therapy is used in the treatment of hormone-dependent cancers, such as prostate and breast cancers, to suppress androgen and estrogen production. In addition, GNRH agonists and antagonists have direct anti-proliferative effects (independent of their hormone regulatory actions) on various reproductive tissue cancer cell lines from prostate (Limonta et al. 1992, 2012, Moretti et al. 1996, Angelucci et al. 2004, Morgan et al. 2011a), breast (Blankenstein et al. 1985, Miller et al. 1985, Eidne et al. 1987, Marini et al. 1994, Emons et al. 2003, Finch et al. 2004), ovary (Emons et al. 1989, 1993b, Grundker et al. 2000, 2001, 2002, Maudsley et al. 2004), and endometrium (Emons et al. 1993a, Grundker et al. 2001, 2002, Acharya et al. 2008). Depending on the cellular phenotype, intense signaling from activated GNRH receptor (GNRHR) can induce cell cycle arrest in G2, with or without concomitant induction of apoptosis. The activated receptor couples to Gq/11 and elicits rapid transient phospholipase C activation, mobilization of intracellular calcium (via inositol trisphosphate (IP3)), protein kinase C activation (via diacylglycerol (DAG)) and activation of MAP kinase, and stress-activated kinase signaling (ERK, JNK, and p38) (Morgan et al. 2008). A role for Gi has been proposed by various investigators but has yet to be critically tested beyond the application of pertussis toxin in co-treatment assays and this contrasts with a crucial role for Gq/11(White et al. 2008).
Although inappropriate signaling results in cellular stress, the details concerning how this stress is converted into a commitment to growth arrest and/or apoptosis are largely uncharacterized. The cellular response is likely to be complex, with changes in gene transcription and regulation of proteins affecting functions of key importance to cell fate. More details concerning the response to GNRHR activation are required in order to understand the anti-proliferative mechanism and to explain why certain cells are more sensitive than others, even though they express similar levels of GNRHR (Morgan et al. 2008). A high level of GNRHR expression at the cell surface correlates with responsiveness to GNRH (Morgan et al. 2008), supporting the hypothesis that there is a requirement for direct interaction between GNRHR and agonist at the cell surface. Identifying the determinants of sensitivity to GNRH analogs would potentially allow sensitive tumors to be selected for treatment.
In order to identify signaling factors required for response to the potent GNRH superagonist, Triptorelin, we employed transcript profiling and protein array analysis of the model human HEK293 (SCL60) cells in vitro and in tumor xenografts to identify markers likely to reflect the anti-proliferative mechanism. This model is a HEK293 cell line transfected with a high level of the GNRHR (Morgan et al. 2008). In most published studies of cancer cells, the presence of GNRHR is inferred on the basis of RT-PCR detection of mRNA and/or by detection of ligand binding to whole cell lysates. In those instances, detection of GNRHR mRNA cannot reliably indicate how much functional GNRHR is present and ligand binding assays usually need to be pushed to the limit of detection sensitivity to infer specific GNRH analog binding. Using HEK293 cells transfected to overexpress GNRHR circumvents these problems and direct comparison can be made to wild-type HEK293 cells. The utility of transfected cell studies has been re-iterated recently (Morgan et al. 2011b).
Our strategy extends preliminary data generated using mouse pituitary tumor LβT2 (White et al. 2008), which serves as a useful benchmark comparison (Morgan et al. 2008). We discovered dynamic changes in gene transcription and altered protein phosphorylation in pathways, which shed more light on the anti-proliferative mechanism of GNRHR activation, and suggest ways in which its effectiveness may be improved.
SCL60 cells are HEK293 cells stably transfected with a high level of functional rat GNRHR (Morgan et al. 2008). SCL60 cells express surface levels of GNRHR similar to that of GNRHR at the surface of mouse embryo pituitary gonadotrope cell line LβT2 (White et al. 2008). This level is similar to that found in mature pituitary gonadotrope cells and at least 100-fold higher than surface receptor levels in any cancer cell line thought to express endogenous GNRHR (Morgan et al. 2008, 2011a).
SCL215 cells stably express a rat GNRHR fused to a catfish GNRHR C-terminal cytoplasmic domain (under G418 selection). The fusion protein binds GNRH analogs, but this does not activate signaling.
HEK293, SCL60, and SCL215 cells were cultured in DMEM with 10% fetal bovine serum. SCL60 and SCL215 cells were supplemented with G418 antibiotic (0.5 mg/ml). For all these cell lines, tissue culture plates were coated with a diluted Matrigel solution (200 μl Matrigel (BD Biosciences, Oxford, UK) per 6 ml DMEM media, 22 °C for 1–2 h, excess removed before adding cells) to assist cell adherence. Cell doubling times for each of the cell lines in basal conditions are similar (∼22 h).
SCL60 or HEK293 cells were treated with 100 nM Triptorelin (Sigma), or an appropriately diluted 20% propylene glycol (Sigma) solution (final concentration: 0.02% propylene glycol). RNA was isolated at 0, 0.5, 1, 2, 8, and 24 h after treatment from four independent experiments on different days using the Absolutely RNA Miniprep kit (Stratagene, Leicester, UK) according to the manufacturer's instructions. Purified RNA was biotin labeled using the Illumina TotalPrep RNA Amplification Kit (Ambion, Huntingdon, UK) according to the manufacturer's instructions. Labeled RNA was hybridized to Illumina HT12 BeadChips and scanned at the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. The gene expression data have been submitted to NCBI's Gene Expression Omnibus and is accessible through GEO Series accession number GSE27467. Gene expression analysis was performed using the open source statistical programming language, R (Ihaka & Gentleman 1996), and associated Bioconductor packages (Gentleman et al. 2004). Data were filtered to remove unreliably detected probes and one outlier replicate and then quantile-normalized using the Beadarray (Dunning et al. 2007) package. Differential expression was determined using Rank Products analysis (Breitling et al. 2004) with 5% false discovery rate.
Cells were treated with Triptorelin (100 nM) or 0.02% propylene glycol solution (vehicle control) for up to 72 h before being trypsinized, pelleted, and resuspended in pH 7.6 citrate buffer. Samples were stored at −20 °C until analysis and were then thawed to room temperature. The cells were incubated at room temperature with 0.003% trypsin solution (450 μl; 0.003% trypsin, 3.4 mM tri-sodium citrate, 0.1% NP40, 1.5 mM spermine hydrochloride, and 0.5 mM Tris base) for 2 min with agitation and then with a second solution (375 μl; 0.05% trypsin inhibitor, and 0.01% w/v RNase A) for 10 min. Finally, cells were treated with 250 μl propidium iodide solution (416 μg/ml propidium iodide, 1.16 mg/ml spermine tetrahydrochloride solution) on ice and in the dark for 10 min. The samples were analyzed using a BD FACSAriaII SORP Flow Cytometer (Becton Dickinson, Oxford, UK) and BD FACSDiva software (Becton Dickinson, Version 6.1.2).
Tumors were derived from the GNRHR-transfected HEK293 cell line, SCL60, by s.c. bilateral implantation of these cells into the flank of athymic nude female mice (Morgan et al. 2008). Nine mice with 11 tumors were treated with Triptorelin (10 μg/mouse, 0.1 ml). Ten mice with 12 tumors were injected with a 20% propylene glycol solution (0.1 ml). Treatment was initiated when tumors were 50–100 mm3 in size. Xenograft material was collected at days 4 and 7 after treatment.
Samples from three tumors following treatment with Triptorelin at day 4 and 7, along with six corresponding controls, were analyzed using the V250 antibody array (Eurogentec Ltd., Southampton, UK). This array comprises 117 pairs of antibodies to detect phosphorylated and non-phosphorylated forms of proteins that are typically dysregulated in cancer-related signaling. A full list of antibodies used is shown in Supplementary Table 1, see section on supplementary data given at the end of this article. Binding of each antibody to its target results in an emission fluorescence, whose intensity is proportional to the level of the target protein. The intensity score for each phosphorylated protein was normalized by Eurogentec Ltd. to that of its non-phosphorylated counterpart.
A tissue microarray (TMA) was constructed with five Triptorelin-treated and six untreated SCL60 xenografts in biological triplicate as described previously (Kononen et al. 1998). Hydrated TMA sections were incubated with primary antibody (rabbit anti-Cleaved Caspase 3 (Asp175; 1:100), rabbit anti-Phospho-Histone H3 (Ser10; 1:200), anti-nuclear factor kappa B (NF-κB) (1:00, Cell Signaling), or anti-pNF-κB (1: Cell Signaling, Hitchin, UK) for 1 h at room temperature and were detected via DakoCytomation envision/HRP Kit (K4003) (Dako, Ely, Cambridgeshire, UK). Finally, all the slides were counter-stained in hematoxylin for 20 s, dehydrated, and mounted. After staining, slides were observed by 400× magnification and a histoscore per core per slide was calculated.
Protein was isolated from SCL60, HEK293, and SCL215 cells following treatment with Triptorelin (100 nM) or control for 0, 0.5, 1, 2, 4, 8, or 24 h from three independent experiments. Samples were diluted to 2 mg/ml and then twofold serially diluted to produce five dilutions of each sample. Each dilution was spotted (Spurrier et al. 2008) in triplicate onto each pad of a 2-pad FAST nitrocellulose-coated glass slide (Whatman, Lutterworth, UK) using a BioRobotics Microgrid (Isogen Life Science, De Meern, The Netherlands). Samples were carefully distributed over the pads to ensure that a balance of control and treated samples was spotted by each pin. Slides were blocked with PBS:Li-Cor Blocking Buffer (1:1, 1 h RT) before incubation with primary antibody (overnight 4 °C). Phosphoprotein (p) expression was measured and compared with total (t) levels of expression.
Primary antibodies were Rabbit polyclonal, from Cell Signaling Technology UK, and diluted 1:50 unless otherwise stated: Anti-P21 (mouse, 1:150), anti-tPTEN (mouse, 1:300), anti-pPTEN (Ser80/Thr382/383), anti-tmTOR (1:300), anti-pmTOR (Ser2448), anti-tCDK2, anti-pCDK2, anti-tAKT (mouse, 1:1000), anti-pAKT (Ser473), anti-tNF-κB, anti-pNF-κB (Ser529), anti-tCyclinD1 (mouse, 1:300), anti-pCyclinD1 (Thr286), Ki67 (Dako, mouse, 1:250), anti-P38 (1:100), anti-pP38 (1:100), pHistone H3 (Ser10, 1:100), PI3K p110α (1:133), pERα (mouse, 1:100), tERα (Neomarkers, Maybridge, Tintagel, UK; 1:250), tCAV1, pCav1 (Tyr14), pMet (Tyr1349), tMet (mouse), pCHK2 (Ser516), tERK (Thr 202/204 for ERK1 and Thr 185/187 for ERK2) (mouse), pERK (1:100), P53 (mouse), and GNRHR (Leica, mouse). Slides were washed with PBS–0.1%Tween 20 (3×5 min) before applying secondary antibody diluted in Li-Cor blocking buffer (45 min RT, dark). The slides were washed in the dark with PBS–0.1% Tween 20 (3×5 min), PBS (3×5 min), and then dried at 50 °C. The slides were scanned on a Li-Cor Odyssey scanner at 680 and 780 nm. The image was analyzed using MicroVigene RPPA Analysis module software (VigeneTech, Carlisle, MA, USA). The means of the triplicate dilutions are used to produce a curve for each sample. The y-intercept is used as a relative measure of protein concentration between curves. This quantitative measurement is used in further analysis. Measurements for phosphoproteins were normalized to the corresponding total protein except for Ki67 and pHH3.
SCL60 cells were seeded into 12-well plates at 1×106 cells/ml. After 48 h, the cells were washed in serum-free media and then treated with 3 μM 15d-PGJ2 (NF-κB inhibitor) or vehicle control (dimethyl sulfoxide) in serum-free media for 30 min before addition of 100 nM Triptorelin or vehicle control (final concentration: 0.02% propylene glycol) in complete media with serum. After 4 days, cell growth was measured by sulforhodamine B assay as described previously (Skehan et al. 1990).
Triptorelin elicited 63% inhibition of SCL60 cell growth after 5 days of treatment but did not affect growth of untransfected parental (HEK293) cells or those transfected with an inactivating mutant GNRHR (SCL215) (Fig. 1A). Flow cytometric analysis of the cells demonstrated that the anti-proliferative effect of Triptorelin in SCL60 cells was associated with an accumulation of cells in the S and G2/M phases of the cell cycle at 24 and 48 h after treatment compared with vehicle-treated control cells (Fig. 1B; Supplementary Figure 1, see section on supplementary data given at the end of this article). There was a significant increase in cleavage of the caspase-mediated apoptosis marker poly (ADP-ribose) polymerase (PARP; Fig. 1C). This increase was small after 48-h treatment with Triptorelin but was much more pronounced after 72–96 h (Fig. 1C). These results reproduce reported results for SCL60 cells (Morgan et al. 2008, 2011a).
To explore the baseline differences in GNRHR-mediated signaling between these responsive and nonresponsive cell lines, we compared the global gene expression profile of the GNRHR-expressing SCL60 cell line with the parental cell line, HEK293. Over 4700 probes were consistently differentially expressed between replicate cultures of these cell lines (∼18% of detected probes on the microarray) using Rank Products analysis with 5% false positive rate). Genes that had higher expression in the GNRHR-expressing cells included genes involved in adhesion (CD44 and TACSTD1 (EPCAM)) and transcriptional regulation (SOX11, TCEAL3, and RUNX3), while genes that had significantly lower expression in SCL60 cells compared with HEK293 cells encoded many transcription regulators (including seven zinc finger proteins) and several proteins involved in adhesion (PCDH17, PCDH10, and SH3PXD2A) (Supplementary Table 1).
We next assessed the effect of Triptorelin treatment on gene expression in SCL60 cells before (0) and 0.5, 1, 2, 8, and 24 h after treatment. The greatest number of differentially expressed genes (>1000) occurred after 8 h treatment with Triptorelin (Fig. 2A), with a higher proportion of genes upregulated rather than downregulated at the early time points (0.5–2 h). Downregulated genes were more apparent after 2 h, presumably reflecting a secondary response, influenced in part by the primary response. The online pathway annotation tool, DAVID (Huang da et al. 2009), was used to determine which pathways were significantly enriched among the genes differentially expressed between SCL60 control and treated cells. Genes that were increased following treatment represented components of the cell cycle, MAPK and p53 signaling pathways, whereas transcripts that were decreased included cell cycle genes (Table 1). Clustering the most strongly upregulated genes in response to Triptorelin treatment in SCL60 cells showed at least three clusters of temporal expression (Fig. 2B). The ‘early genes’ (0.5–1 h) included early growth response 1 (EGR1), the MAP kinase inactivator DUSP1 (MKP1), along with the transcription factors JUNB, FOS, and FOSB (Fig. 2B). Genes that were increased later (8–24 h) included the epithelial cell stress chemokine, IL8, and the glycoprotein common gonadotropin subunit alpha (CGA), a GNRH signaling target gene in pituitary gonadotrope cells (Fig. 2B). The most downregulated genes included the cell motility SLIT-ROBO Rho GTPase activating protein SRGAP3, and the growth factor modulator IGF binding protein 5 (Fig. 2C). These genes were also mostly lower in HEK293 cells compared with SCL60-untreated cells but were unaffected by Triptorelin treatment in HEK293 cells (Fig. 2C). Of the genes that were significantly higher in SCL60 cells compared with HEK293 cells, 138 were also consistently increased with Triptorelin treatment in SCL60 cells, while 82 genes were downregulated after treatment and higher in SCL60 cells compared with HEK293 cells, including fibroblast growth factor receptor (FGFR) and CACN (involved in calcium channel formation). Pathways associated with these genes included MAPK and cell cycle signaling (full lists are given in Supplementary Table 1). Looking more closely at the timing and processes of transcripts altered by GNRHR activation, it becomes clear that the changes classify into several distinct temporal and functional groups (Fig. 3). These patterns can be summarized as early sustained changes in transcription factors (EGR1, FosB, Fos EGR2, SRF, ATF3, and KLF6), G1/S markers (MCM8 and CHEK2), and signaling apparatus – including regulators of inositol phosphate metabolism and MAP kinase phosphatases (DUSP5, DUSP1, INPP1, and ISYNA1); later and continuing changes in G2/M markers (NDEL1, CDC2, TUBB4, DCTN1, KIF20A, CENPM, CENPF, and RASSF1A) and apoptotic apparatus (EIF5A, KLF10, BAX, and cFLAR); and more transient changes in cytoskeletal components (TPM4, ITGAV, KIF5C, FLRT3, DSTN, MAPT, and DGCR2) and cyclins (CCNA1 and CGRRF1).
In order to establish whether the GNRHR-mediated gene expression changes observed were similar to GNRH-regulated changes in other systems, we compared them to a previous study by Kakar et al. (2003). These investigators reported a list of 68 genes whose expression was changed in mouse LβT2 gonadotrope cells following treatment with a GNRH agonist des-gly10, [D-Ala6]-ethylamide GNRH. Human homologs could be identified for 59 of the mouse genes and these were sufficient to cluster the SCL60 dataset into treated and control groups. Of the 59 orthologous genes, 21 were commonly differentially expressed, including a number of the early response genes EGR1, FOSB, JUNB, and IER2 (Supplementary Table 1), although this study was limited to 1- and 24-h time points.
Building upon the gene expression data, reverse-phase protein array (RPPA) technology was used as a screening tool to characterize the posttranscriptional response to GNRHR activation. The focus was on representative members of cell cycle components, growth regulators, MAPK signaling, and cell survival modulators, as these were suggested to be important from the gene expression data (Fig. 4A). Levels of pERK were increased, as expected from previous studies (Morgan et al. 2008) and levels of pNF-κB expression were also increased (Fig. 4B and C and Supplementary Figure 3, see section on supplementary data given at the end of this article). In contrast, pAkt decreased in a more gradual manner and pPTEN expression demonstrated a transient reduction (Fig. 4C and Supplementary Figure 3). The level of p-histone H3 showed a reduction initially but was increased after 24 h and may reflect cells accumulating in the G2/M phase of the cell cycle. The overall reduction in pAkt and increases in the levels of pERK and pNF-κB expression were confirmed by western blot (Fig. 4B, C and D).
We next assessed the effect of Triptorelin on GNRH signaling in vivo. Consistent with previous findings (Morgan et al. 2008), Triptorelin was found to cause a significant reduction in growth of SCL60 xenograft tumors, and we established that the GNRH agonist had no effect on parental (HEK293) or mutated receptor-transfected (SCL215) cells (Fig. 5A). Immunostaining revealed decreased levels of p-Histone H3, consistent with reduced proliferation (Fig. 5B) and increased caspase 3, consistent with increased apoptosis following Triptorelin treatment for 4 and 7 days compared with untreated control tumors (Fig. 5B, P=0.004). Representative images are shown in Supplementary Figure 2, see section on supplementary data given at the end of this article.
To determine whether similar pathways were changed in response to a GNRH agonist in vivo, we used an antibody array with 117 pairs of antibodies (Supplementary Table 1) to detect both the phosphorylated and non-phosphorylated forms of selected proteins in SCL60 xenografts treated with Triptorelin. There were increases in phosphorylation of both NF-κB-p65 and IκBϵ after 4 days, consistent with the RPPA in vitro analysis and suggesting a possible involvement of the NF-κB survival signaling pathway in response to Triptorelin treatment. Also consistent with the RPPA data was the reduction in phosphorylated Akt at day 7. Changes observed in Chk2, p27, and CDC25C may be representative of the disruption to cell cycle progression. Dynamic changes in levels of phosphoproteins occurred: these included a gradual decrease in pMET, a transient increase in AMPK1, and a sustained increase in pMYC (Fig. 5C).
As both in vitro RPPA and in vivo phosphoprotein array data highlighted that NF-κB signaling was activated in response to Triptorelin treatment, we investigated the in vitro gene expression patterns of several NF-κB pathway members in SCL60 cells following treatment with Triptorelin (Fig. 6A). NF-κB1 expression peaked at 8 h, whereas NF-κBIA and MAPK8 (an activator of NF-κB-p105) were highest after just 2 h, while gene expression levels of IKBKG and IKBKB were largely unchanged. To validate the increase in pNF-κB seen upon GNRH stimulation in vivo, we next performed immunohistochemistry on the xenograft tumors and found pNF-κB to be significantly (P=0.009) higher following treatment with Triptorelin (Fig. 6B). Representative images are shown in Supplementary Figure 4, see section on supplementary data given at the end of this article.
To evaluate NF-κB signaling as a possible pathway to target in combination with GNRHR activation, we inhibited the pathway in SCL60 cells in vitro. After 4 days, we observed significant reduction of SCL60 cell growth when treated with either 100 nM Triptorelin or 3 μM 15d-PGJ2 (NF-κB inhibitor) (Straus et al. 2000) and enhanced growth repression when both were used in combination (Fig. 6C), suggesting an additive effect. In contrast, none of these treatments influenced the growth of the parental HEK293 cells.
Various G protein-coupled receptors (GPCRs) at the cell surface can influence cancer cell growth. Intense activation of the GNRHR, a Gq/11-coupled peptide hormone GPCR, can inhibit the proliferation of certain but not all cancer cell types. An improved understanding of how GNRH agonist anti-proliferative effects are elicited could address how certain cells are able to avoid the resulting downstream growth arrest signaling and treatment could be tailored more appropriately. Detailing the cellular responses to GPCR activation is a difficult process due to signaling pathway complexity and the temporal changes that occur downstream from receptor activation. In this study, we used global gene and protein expression approaches to explore GNRHR signaling in relation to cell growth inhibition. We identified a number of candidate signaling pathways that may be involved in mediating and modulating the direct anti-proliferative effect of GNRH agonists in vitro and in vivo. The transcriptional and proteomic changes observed suggest a model summarized in Fig. 7 where transcription factors are increased as an early response and maintained following Triptorelin treatment. Genes involved in apoptosis (e.g. EIF5A and cFLAR) and G1/S transition signaling (e.g. MCM8 and CHEK2) were altered in expression around 1–8 h after treatment, whereas expression of cytoskeletal (e.g. TPM4, ITGAV, DSTN, MAPT and DGCR2) and G2/M-related (NDEL1, CDC2 (CDK1), TUBB4 (TUBB4A), DCTN1, KIF20A, CENPM, CENPF, RASSF1A) genes were changed around 8–24 h. The increased expression of early response genes such as FOS and EGR1 after 30 min to 1 or 2 h was consistent with previous observations of an intense and rapid increase in ERK phosphorylation immediately following GNRHR stimulation in SCL60 cells in vitro (Morgan et al. 2008), translocation to the nucleus, and the activation of these transcription factors. FOS gene family members encode proteins that dimerize with proteins of the JUN family to form the transcription factor complex AP-1 (Salisbury et al. 2008). The increased expression of both FOS and JUN family members make this a likely mechanism of transcriptional activation in SCL60 cells.
Flow cytometric analysis suggested that Triptorelin may induce G2/M arrest and accumulation in S phase after 24 and 48 h. A number of cell cycle genes are differentially expressed, which may support this, particularly the increase in MAD2 mitotic arrest deficient-like 1 (MAD2L1), which encodes a protein that forms part of the spindle assembly checkpoint and prevents anaphase until chromosomes are properly aligned. Another component of the anaphase checkpoint, BUB3, was also increased (Taylor et al. 1998), along with the growth arrest and DNA-damage-inducible genes GADD45A and GADD45B. These genes have been shown to activate the p38/JNK pathway to cause G2/M arrest (Zhu et al. 2009, Cho et al. 2010), and GADD45B has been shown to play a role in mediating Fas-induced apoptosis by enhancing the interaction between p38 and Rb (Cho et al. 2010). Several cell cycle-related proteins were also differentially phosphorylated: p27kip and CDC25C were increased, while Chk2 was decreased after 7 days. Changes in the phosphorylation levels of the apoptosis regulators BCL2 and BAD were also observed.
Although ERK activation often drives proliferation, it has been associated with cell death in many different cell types (Zhuang & Schnellmann 2006, Mebratu & Tesfaigzi 2009). ERK-mediated G2 arrest is thought to be dependent on PKC (Barboule et al. 1999, Dangi et al. 2006) and MEK1 (Dangi et al. 2006, Astuti et al. 2009). GNRHR signals through Gαq to activate PLCβ, causing PIP2 cleavage and generation of DAG. IP3 activates calcium channels in the endoplasmic reticulum to release Ca2+ and PKC is activated by DAG and Ca2+. Once active, PKC phosphorylates Raf, which in turn activates MEK and downstream ERK. We have previously shown that the GNRHR-mediated anti-proliferative effect in SCL60 cells is dependent on PKC (Morgan et al. 2008). The ERK activation observed after Triptorelin treatment may be mediated through PKC and may be responsible for the G2/M arrest observed in SCL60 cells.
Later-stage (8–24 h) gene expression changes reflected known GNRHR signaling effects exemplified by the CGA transcript, a stress response (IL8) and growth modulation (IGFBP5, FGFR, and Met). Changes in protein phosphorylation suggested modulation of membrane protein function (Cav-1), growth signaling (Met), metabolism (AMPK), cell motility (SRGAP3), and a pro-survival response (NF-κB). Clearly, the status of the cell cycle apparatus was altered with changes in p27, CDC25c, and Chk2.
NF-κB signaling was highlighted by both in vivo and in vitro approaches; the additive effect of Triptorelin plus 15d-PGJ(2) on growth inhibition may represent a useful target for drug combination treatments. Triptorelin has previously been shown to induce NF-κB activation in ovarian cancer cells (EFO-21 and EFO-27), which inhibited doxorubicin-induced apoptosis (Grundker et al. 2000). As 15d-PGJ(2) elicits effects via PPAR-gamma and NF-κB, the effect on growth in combination with Triptorelin may be somewhat cell type specific. This phenomenon will require further investigation. The results of the current study indicate the intricacy of the regulatory response to GNRHR activation. We found good agreement between our gene expression data and a previous study of gene expression changes in mouse LβT2 gonadotrope cells following treatment with a GNRH agonist (Kakar et al. 2003). However, our recent findings that the overexpression of GNRHR alone is not sufficient to facilitate an anti-proliferative response to Triptorelin in several breast cancer cell lines (Morgan et al. 2011b) provides an excellent opportunity to interrogate the factors and mechanisms involved in cell-type-specific differences that mediate the direct anti-proliferative effect of GNRH agonists. These may entail analyses of the changes occurring in WPE-1-NB26 cells, which exhibit cell cycle arrest without prominent commitment to apoptosis and manipulation of gene expression in MCF-7 cells, which escape GNRHR-mediated growth inhibition.
In conclusion, in vitro and in vivo transcriptomic and proteomic approaches were used to characterize the anti-proliferative effects of a GNRH agonist at the molecular signaling level. The anti-proliferative response induced by GNRHR activation appears to result in apoptosis and G2/M arrest mediated via a coordinated dynamic pattern of MAPK, cell cycle, apoptotic, and cytoskeletal-related signaling. Key regulators pAKT and pERK were repressed and induced respectively, while pNF-κB was activated and may represent a useful target for enhancing this intriguing anti-proliferative response.
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-12-0192.
*K Morgan is now at Respiratory Medicine, University of Hull, Hull, UK
The authors acknowledge the financial support of NHS Research Scotland (NRS), through Edinburgh Clinical Research Facility.
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
This work was supported by funding from Breakthrough Breast Cancer, Medical Research Council and the Scottish Funding Council.
|Acharya CR,Hsu DS,Anders CK,Anguiano A,Salter KH,Walters KS,Redman RC,Tuchman SA,Moylan CA,Mukherjee S,et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancerJournal of the American Medical Association299Year: 200815741587doi:10.1001/jama.299.13.157418387932|
|Angelucci C,Iacopino F,Lama G,Capucci S,Zelano G,Boca M,Pistilli A,Sica G. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cellsAnticancer Research24Year: 20042729273815517879|
|Astuti P,Pike T,Widberg C,Payne E,Harding A,Hancock J,Gabrielli B. MAPK pathway activation delays G2/M progression by destabilizing Cdc25BJournal of Biological Chemistry284Year: 20093378133788doi:10.1074/jbc.M109.02751619801682|
|Barboule N,Lafon C,Chadebech P,Vidal S,Valette A. Involvement of p21 in the PKC-induced regulation of the G2/M cell cycle transitionFEBS Letters444Year: 19993237doi:10.1016/S0014-5793(99)00022-810037143|
|Blankenstein MA,Henkelman MS,Klijn JG. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cellsEuropean Journal of Cancer & Clinical Oncology21Year: 198514931499doi:10.1016/0277-5379(85)90244-5|
|Breitling R,Armengaud P,Amtmann A,Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experimentsFEBS Letters573Year: 20048392doi:10.1016/j.febslet.2004.07.05515327980|
|Cho HJ,Park SM,Hwang EM,Baek KE,Kim IK,Nam IK,Im MJ,Park SH,Bae S,Park JY,et al. Gadd45b mediates Fas-induced apoptosis by enhancing the interaction between p38 and retinoblastoma tumor suppressorJournal of Biological Chemistry285Year: 20102550025505doi:10.1074/jbc.M109.09141320558744|
|Dangi S,Chen FM,Shapiro P. Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1Cell Proliferation39Year: 2006261279doi:10.1111/j.1365-2184.2006.00388.x16872362|
|Dunning MJ,Smith ML,Ritchie ME,Tavare S. beadarray: R classes and methods for Illumina bead-based dataBioinformatics23Year: 200721832184doi:10.1093/bioinformatics/btm31117586828|
|Eidne KA,Flanagan CA,Harris NS,Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonistsJournal of Clinical Endocrinology and Metabolism64Year: 1987425432doi:10.1210/jcem-64-3-4253029154|
|Emons G,Pahwa GS,Brack C,Sturm R,Oberheuser F,Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomataEuropean Journal of Cancer & Clinical Oncology25Year: 1989215221doi:10.1016/0277-5379(89)90011-4|
|Emons G,Schroder B,Ortmann O,Westphalen S,Schulz KD,Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell linesJournal of Clinical Endocrinology and Metabolism77Year: 1993a14581464doi:10.1210/jc.77.6.14588263128|
|Emons G,Ortmann O,Becker M,Irmer G,Springer B,Laun R,Holzel F,Schulz KD,Schally AV. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell linesCancer Research53Year: 1993b543954468221683|
|Emons G,Grundker C,Gunthert AR,Westphalen S,Kavanagh J,Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancersEndocrine-Related Cancer10Year: 2003291299doi:10.1677/erc.0.010029112790790|
|Finch AR,Green L,Hislop JN,Kelly E,McArdle CA. Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cellsJournal of Clinical Endocrinology and Metabolism89Year: 200418231832doi:10.1210/jc.2003-03078715070951|
|Gentleman RC,Carey VJ,Bates DM,Bolstad B,Dettling M,Dudoit S,Ellis B,Gautier L,Ge Y,Gentry J,et al. Bioconductor: open software development for computational biology and bioinformaticsGenome Biology5Year: 2004R80doi:10.1186/gb-2004-5-10-r8015461798|
|Grundker C,Schulz K,Gunthert AR,Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cellsJournal of Clinical Endocrinology and Metabolism85Year: 200038153820doi:10.1210/jc.85.10.381511061544|
|Grundker C,Volker P,Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphataseEndocrinology142Year: 200123692380doi:10.1210/en.142.6.236911356684|
|Grundker C,Gunthert AR,Millar RP,Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferationJournal of Clinical Endocrinology and Metabolism87Year: 200214271430doi:10.1210/jc.87.3.142711889221|
|Huang da W,Sherman BT,Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols4Year: 20094457doi:10.1038/nprot.2008.211|
|Ihaka R,Gentleman R. R: a language for data analysis and graphicsJournal of Computational and Graphical Statistics5Year: 1996299314doi:10.2307/1390807|
|Kakar SS,Winters SJ,Zacharias W,Miller DM,Flynn S. Identification of distinct gene expression profiles associated with treatment of LbetaT2 cells with gonadotropin-releasing hormone agonist using microarray analysisGene308Year: 20036777doi:10.1016/S0378-1119(03)00446-312711391|
|Kononen J,Bubendorf L,Kallioniemi A,Barlund M,Schraml P,Leighton S,Torhorst J,Mihatsch MJ,Sauter G,Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine4Year: 1998844847doi:10.1038/nm0798-844|
|Limonta P,Dondi D,Moretti RM,Maggi R,Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaPJournal of Clinical Endocrinology and Metabolism75Year: 1992207212doi:10.1210/jc.75.1.2071320049|
|Limonta P,Marelli MM,Mai S,Motta M,Martini L,Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategiesEndocrine Reviews33Year: 2012784811doi:10.1210/er.2012-101422778172|
|Marini L,Iacopino F,Schinzari G,Robustelli della Cuna FS,Mantovani G,Sica G. Direct antiproliferative effect of triptorelin on human breast cancer cellsAnticancer Research14Year: 1994188118857847821|
|Maudsley S,Davidson L,Pawson AJ,Chan R,Lopez de Maturana R,Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptorCancer Research64Year: 200475337544doi:10.1158/0008-5472.CAN-04-136015492280|
|Mebratu Y,Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?Cell Cycle8Year: 200911681175doi:10.4161/cc.8.8.814719282669|
|Miller WR,Scott WN,Morris R,Fraser HM,Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonistNature313Year: 1985231233doi:10.1038/313231a02982100|
|Moretti RM,Marelli MM,Dondi D,Poletti A,Martini L,Motta M,Limonta P. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145Journal of Clinical Endocrinology and Metabolism81Year: 199639303937doi:10.1210/jc.81.11.39308923840|
|Morgan K,Stewart AJ,Miller N,Mullen P,Muir M,Dodds M,Medda F,Harrison D,Langdon S,Millar RP. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivoCancer Research68Year: 200863316340doi:10.1158/0008-5472.CAN-08-019718676858|
|Morgan K,Stavrou E,Leighton SP,Miller N,Sellar R,Millar RP. Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cellsProstate71Year: 2011a915928doi:10.1002/pros.2130821541969|
|Morgan K,Meyer C,Miller N,Sims AH,Cagnan I,Faratian D,Harrison DJ,Millar RP,Langdon SP. GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell linesBMC Cancer11Year: 2011b476doi:10.1186/1471-2407-11-47622051164|
|Salisbury TB,Binder AK,Nilson JH. Welcoming β-catenin to the gonadotropin-releasing hormone transcriptional network in gonadotropesMolecular Endocrinology22Year: 200812951303doi:10.1210/me.2007-051518218726|
|Skehan P,Storeng R,Scudiero D,Monks A,McMahon J,Vistica D,Warren JT,Bokesch H,Kenney S,Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screeningJournal of the National Cancer Institute82Year: 199011071112doi:10.1093/jnci/82.13.11072359136|
|Spurrier B,Ramalingam S,Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysisNature Protocols3Year: 200817961808doi:10.1038/nprot.2008.179|
|Straus DS,Pascual G,Li M,Welch JS,Ricote M,Hsiang CH,Sengchanthalangsy LL,Ghosh G,Glass CK. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathwayPNAS97Year: 200048444849doi:10.1073/pnas.97.9.484410781090|
|Taylor SS,Ha E,McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinaseJournal of Cell Biology142Year: 1998111doi:10.1083/jcb.142.1.19660858|
|White CD,Coetsee M,Morgan K,Flanagan CA,Millar RP,Lu ZL. A crucial role for Galphaq/11, but not Galphai/o or Galphas, in gonadotropin-releasing hormone receptor-mediated cell growth inhibitionMolecular Endocrinology22Year: 200825202530doi:10.1210/me.2008-012218801931|
|Zhu N,Shao Y,Xu L,Yu L,Sun L. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cellsMolecular Biology Reports36Year: 200920752085doi:10.1007/s11033-008-9419-919048389|
|Zhuang S,Schnellmann RG. A death-promoting role for extracellular signal-regulated kinaseJournal of Pharmacology and Experimental Therapeutics319Year: 2006991997doi:10.1124/jpet.106.10736716801453|
Keywords: Keywords GnRh, NFκB, triptorelin, xenograft, SCL60.
Previous Document: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: backgr...
Next Document: The intestinal microbiome, probiotics and prebiotics in neurogastroenterology.